CA-XSOLLA
7.3.2024 14:01:26 CET | Business Wire | Press release
Xsolla, a global video game commerce company, announces Xsolla Wallet, highlighting its commitment to empowering the global creator economy within the video game industry. Our mission is to provide equal access for developers, creators, and everyone in the creator economy with embedded finance solutions for the video game industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307401699/en/
(Graphic: Xsolla)
The Xsolla Wallet is a game-changing solution offering embedded finance options specifically designed for developers and creators. The initiative helps developers overcome monetization and engagement challenges and simplifies the process of providing attractive incentives for creators. It enhances the efficiency and immediacy of their earning and spending experience while ensuring global compliance.
Recognizing the complexities of managing successful global creator programs, Xsolla will help alleviate these pain points, enabling developers to focus on what they do best: creating engaging gaming experiences.
For Developers: Xsolla Wallet simplifies access to embedded finance services and streamlines onboarding and compliance, integrating these critical aspects within the creators' wallet accounts.
- Simplify Creator Incentives: Tailored to ease the complexities of managing creator programs, Xsolla Wallet ensures developers can provide attractive and compliant earnings for creators across different regions.
- Ease Compliance Burdens: With integrated KYC (Know Your Customer) and tax interview services, Xsolla Wallet significantly reduces the complexity associated with global compliance, allowing developers to focus on innovation rather than administrative tasks.
- Expand and Accelerate Influence: Leveraging the vast reach of the Xsolla gaming ecosystem, developers can use the Xsolla Partner Network (XPN) to attract, manage and incentivize creators and influencers.
For Creators: Xsolla Wallet empowers creators and influencers to pay, get paid and manage earnings, transforming their content into viable revenue sources.
- Pay: Creators will have a direct, immediate, and convenient way to spend their earnings using the Xsolla Mastercard.
- Get Paid: Creators can choose an instant virtual Xsolla Mastercard, amongst other payout options, to enable easy and immediate access to their earnings.
- Manage Earnings: Creators can seamlessly aggregate their earnings from platforms. This means creators can manage diverse income streams, from merchandise sales to crowdfunding, in their Xsolla Wallet.
"By bringing together our expertise and the Xsolla Wallet's embedded finance functionality, we are bringing developers and creators together in an unparalleled financial ecosystem tailored for video games," described David Stelzer, President of Xsolla. "We aim to provide an equal opportunity for every developer, creator, and influencer to have fast and secure access to ways to monetize their work in the global creator economy."
“As a long-standing supporter of the video gaming community, Mastercard is thrilled to continue building on our partnership with Xsolla, delivering choice and value to creators and developers alike with the launch of the Xsolla Mastercard,” said Sherri Haymond, EVP, Global Digital Partnerships at Mastercard. “Together we’re enabling convenient, seamless payments options that add tools to developers’ toolkits, help solve challenges for creators and foster an inclusive gaming community for all.”
Xsolla Wallet is a key component in a new suite of tools empowering game developers and creators. It reflects Xsolla's dedication to creating solutions that address content creators' immediate needs and foster a more supportive and productive environment for their creations through an embedded finance partnership with Paysafe and a card for creators partnership with Mastercard.
"We are proud to strengthen our partnership with Xsolla to provide value and exceed customer expectations with our payment solutions, further enhancing gamers' playing and payment experience globally," said Aaron Gale, VP of Sales & Account Management, Video Games at Paysafe. "Every gaming experience starts with a payment, and we are dedicated to turning these transactions into part of the overall experience, to fuel the fun and champion customer engagement and loyalty."
For more details about Xsolla Wallet, please visit: xsolla.pro/wallet
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
About Paysafe
Paysafe Limited (“Paysafe”) (NYSE: PSFE) (PSFE.WS) is a leading payments platform with an extensive track record of serving merchants and consumers in the global entertainment sectors. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through industry-leading capabilities in payment processing, digital wallet, and online cash solutions. With over 20 years of online payment experience, an annualized transactional volume of over $130 billion in 2022, and approximately 3,300 employees located in 12+ countries, Paysafe connects businesses and consumers across 100 payment types in over 40 currencies around the world. Delivered through an integrated platform, Paysafe solutions are geared toward mobile-initiated transactions, real-time analytics and the convergence between brick-and-mortar and online payments. Further information is available at www.paysafe.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307401699/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom